Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Bisphosphonate | Research

Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw

Authors: Hong Mu, Ying Pang, Lili Liu, Jingbo Liu, Chunsheng Liu

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Bisphosphonates (BPs) are widely used in clinical practice to prevent and treat bone metabolism-related diseases. Medication-related osteonecrosis of the jaw (MRONJ) is one of the major sequelae of BPs use. Early prediction and intervention of MRONJ are of great significance.

Methods

Ninety-seven patients currently on treatment with BPs or with a history of BPs usage and 45 healthy volunteers undergoing dentoalveolar surgery were included in this study. Participants' serum Semaphorin 4D (Sema4D) levels were measured and analyzed before participants underwent surgery (T0) and after a 12-month follow-up (T1). Kruskal–Wallis test and ROC analysis were used to examine the predictive effect of Sema4D on MRONJ.

Results

Sema4D levels in serum of patients corresponding to confirmed MRONJ were significantly lower at both T0 and T1 time points compared to non-MRONJ and healthy controls. Sema4D has a statistically predictive effect on the occurrence and diagnosis of MRONJ. Serum Sema4D levels were significantly reduced in MRONJ class 3 patients. MRONJ patients who received intravenous BPs had significantly lower Sema4D levels than those who received oral BPs.

Conclusion

Serum Sema4D level has predictive value for the onset of MRONJ in BPs users within 12 weeks after dentoalveolar surgery.
Literature
1.
Yuan F, Peng W, Yang C, Zheng J. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. Int J Surg. 2019;66:1–11.CrossRefPubMed
2.
Black DM, Rosen CJ. Clinical practice postmenopausal osteoporosis. N Engl J Med. 2016;374:254–62.CrossRefPubMed
3.
4.
Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–70.CrossRefPubMed
5.
6.
7.
Kim J, Lee DH, Dziak R, Ciancio S. Bisphosphonate-related osteonecrosis of the jaw: current clinical significance and treatment strategy review. Am J Dent. 2020;33:115–28.PubMed
8.
Ferreira LH Jr, Mendonca KD Jr, de Souza JC, Dos Reis DCS, do Guedes CCFV, de Filice LSC, et al. Bisphosphonate-associated osteonecrosis of the jaw. Minerva Dent Oral Sci. 2021;70:49–57.
9.
Chien HI, Chen LW, Liu WC, Lin CT, Ho YY, Tsai WH, et al. Bisphosphonate-related osteonecrosis of the jaw. Ann Plast Surg. 2021;86:S78–83.CrossRefPubMed
10.
Shibahara T. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med. 2019;247:75–86.CrossRefPubMed
11.
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177–87.CrossRefPubMed
12.
Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7:47.CrossRefPubMedPubMedCentral
13.
14.
Zhang CL, Hong CD, Wang HL, Chen AQ, Zhou YF, Wan Y, et al. The role of semaphorins in small vessels of the eye and brain. Pharmacol Res. 2020;160:105044.CrossRefPubMed
15.
16.
Zhang Y, Liu B, Ma Y, Jin B. Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol. 2013;10:97–8.CrossRefPubMed
17.
Hernandez-Fleming M, Rohrbach EW, Bashaw GJ. Sema-1a reverse signaling promotes midline crossing in response to secreted semaphorins. Cell Rep. 2017;18:174–84.CrossRefPubMedPubMedCentral
18.
19.
Takeuchi Y. Innovation of bisphosphonates for improvement of adherence. Clin Calcium. 2017;27:197–202.PubMed
20.
Baroncelli GI, Bertelloni S. The use of bisphosphonates in pediatrics. Horm Res Paediatr. 2014;82:290–302.CrossRefPubMed
21.
22.
Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26:1251–60.CrossRefPubMed
23.
Lili Liu HM, Pang Ying. Caffeic acid treatment augments the cell proliferation, differentiation, and calcium mineralization in the human osteoblast-Like MG-63 cells. Pharmacogn Mag. 2021;17:6.
24.
Hong Mu YP, Liu Lili, Li F, Wang J. Citral promotes the cell proliferation, differentiation, and calcium mineralization in human osteoblast-like MG-63 Cells. Pharmacogn Mag. 2021;17:5.
25.
26.
Shannon J, Shannon J, Modelevsky S, Grippo AA. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc. 2011;59:2350–5.CrossRefPubMed
27.
Kanwar N, Bakr MM, Meer M, Siddiqi A. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. Br Dent J. 2020;228:886–92.CrossRefPubMed
28.
29.
Mathijssen NM, Buma P, Hannink G. Combining bisphosphonates with allograft bone for implant fixation. Cell Tissue Bank. 2014;15:329–36.CrossRefPubMed
30.
31.
32.
Limoni G, Niquille M. Semaphorins and Plexins in central nervous system patterning: the key to it all? Curr Opin Neurobiol. 2021;66:224–32.CrossRefPubMed
33.
Wu JH, Li YN, Chen AQ, Hong CD, Zhang CL, Wang HL, et al. Inhibition of Sema4D/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med. 2020;12:e10154.CrossRefPubMedPubMedCentral
34.
Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Sakellariou G, Savvidis M, et al. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opin Ther Targets. 2015;19:299–306.CrossRefPubMed
35.
Movila A, Mawardi H, Nishimura K, Kiyama T, Egashira K, Kim JY, et al. Possible pathogenic engagement of soluble Semaphorin 4D produced by gammadeltaT cells in medication-related osteonecrosis of the jaw (MRONJ). Biochem Biophys Res Commun. 2016;480:42–7.CrossRefPubMed
36.
Zhang Y, Wei L, Miron RJ, Zhang Q, Bian Z. Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J Dent Res. 2014;93:1095–100.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw
Authors
Hong Mu
Ying Pang
Lili Liu
Jingbo Liu
Chunsheng Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01095-6

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway

Research

Mitofusin2 expression is associated with podocyte injury in IgA nephropathy

Research

Bacterial pathogens and in-hospital mortality in revision surgery for periprosthetic joint infection of the hip and knee: analysis of 346 patients

Review

Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases

Review

Education on medically unexplained symptoms: a systematic review with a focus on cultural diversity and migrants

Research

Nucleated red blood cells are a predictor of mortality in patients under extracorporeal membrane oxygenation